Course Summary This issue of Rheumatology Nurse Practice will review how telemedicine has evolved in the last decade; how this communication and healthcare delivery modality […]
This issue of Rheumatology Nurse Practice will explore the growing base of knowledge regarding the pathophysiology of RA and how new agents being developed are targeting new pathways in new ways. It will also examine the growing role of biosimilars as they begin to be introduced more regularly into clinical care.
In this issue of Rheumatology Nurse Practice, we explore the options available to measure and track disease activity levels in patients with psoriatic arthritis and offer guidance on how these can be smoothly incorporated into routine clinical practice.
In this issue of Rheumatology Nurse Practice, we’ll follow a hypothetical patient from the moment they leave the rheumatology office with a DMARD prescription, tracing their steps to their insurance company, their local pharmacy (or specialty pharmacy), and their home.
The goal of this activity is to increase awareness in targeted treatments for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), as well as the potential impact of biosimilar medicines in rheumatology clinical practice.
In this issue we will explore the pathways that new agents under investigation for the treatment of psoriatic arthritis (PsA) are targeting. We will also examine the potential role of biosimilars for patients with PsA as they are introduced more commonly into clinical care.
We will look at the association between obesity and rheumatoid arthritis and how the presence of excess weight impacts patient experience and response to disease modifying anti-rheumatic drug therapy. We will also briefly address current thinking surrounding the “obesity paradox.” Lastly, we will explore approaches to weight loss in patients who are overweight or obese and the general benefits of weight loss in this population.
We will take a look at current and anticipated guideline recommendations for treatment of PsA, the efficacy and safety of biologic and other agents, considerations in the selection and switching of therapy, and real-life practice trends.
We will explore the current body of evidence addressing the use of DMARD monotherapy, specifically biologic and targeted synthetic small molecule therapies, in patients with RA. What do the guidelines say about when to prescribe biologics or small molecules, and is monotherapy with these medications ever recommended?
We will provide an introductory level description of the basic immunology and pathophysiology of systemic lupus erythematosus (SLE) that will allow rheumatology nurses and nurse practitioners to better understand and explain key concepts of SLE to their patients.